

Hyoscine BUTYLbromide

Potential SALAD		
Two hyoscine preparations are available - Hyoscine BUTYLbromide and Hyoscine HYDRObromide Check carefully when you are using this monograph to ensure that you are using it appropriately The information in this monograph is specific to Hyoscine BUTYLbromide		
Form	20mg per mL ampoule	Store below 25°C in its original packaging
Reconstitution	Ready diluted • Draw up using a 5 micron filter needle • Use gloves when opening ampoules	
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5%	
Administration	IV Injection	
	Give by slow injection over 3 - 5 minutes. Dilute to a convenient volume with a compatible fluid to aid slow administration due to risk of marked hypotension and anaphylactic shock if given too quickly. Can be given undiluted.	
	SC Injection	
	Withdraw required dose. Give by SC injection.	
	Continuous SC Infusion	
	Dilute with sodium chloride 0.9%	
	IM Injection (see note below)	
	Withdraw the required dose. Inject into a large muscle such as the gluteus or the lateral aspect of the thigh	
Monitoring	• Monitor blood pressure, temperature, heart rate and for signs of anaphylaxis. • Patients with underlying cardiac disease such as heart failure, coronary heart disease, cardiac arrhythmia or hypertension should be carefully monitored. • Ensure resuscitation equipment is readily available.	
Extravasation	Hyoscine BUTYLbromide has a low pH and may cause venous irritation and tissue damage in cases of extravasation.	
Additional Information	• Patients should seek urgent ophthalmological advice if they develop a painful, red eye with loss of vision after administration. • Should not be given by intramuscular injection to patients being treated with anticoagulant drugs since intramuscular haematoma may occur • Administration via syringe driver is unlicensed and may increase the administration risk rating. To mitigate these risks: ○ Contact the Pharmacy Department or Palliative care team for further guidance. ○ Consult the Palliative Care Formulary or the Drug Compatibility Checker accessible via www.medicinescomplete.com	

Information provided relates to Buscopan® (Sanofi) last updated 3/3/26

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications.
 Further information is available from Pharmacy on 22146 or 22542*